Samsung Biologics Co.,Ltd. (207940.KS)
KRW 1083000.0
(2.95%)
KRW 1083000.0
(2.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 377.39 Billion KRW | -69.39% |
| 2022 | 1232.98 Billion KRW | 9.56% |
| 2021 | 1125.35 Billion KRW | 91.56% |
| 2020 | 587.46 Billion KRW | 136.11% |
| 2019 | 248.8 Billion KRW | -48.82% |
| 2018 | 486.11 Billion KRW | 19.37% |
| 2017 | 407.23 Billion KRW | -7.31% |
| 2016 | 439.36 Billion KRW | -35.56% |
| 2015 | 681.79 Billion KRW | 59.6% |
| 2014 | 427.19 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 244.81 Billion KRW | 25.67% |
| 2024 Q1 | 194.8 Billion KRW | -18.76% |
| 2023 Q2 | 1078.56 Billion KRW | -7.43% |
| 2023 Q3 | 487.6 Billion KRW | -54.79% |
| 2023 Q4 | 377.39 Billion KRW | -22.6% |
| 2023 FY | 377.39 Billion KRW | -69.39% |
| 2023 Q1 | 1165.08 Billion KRW | -5.51% |
| 2022 FY | 1232.98 Billion KRW | 9.56% |
| 2022 Q4 | 1232.98 Billion KRW | -23.53% |
| 2022 Q3 | 1612.33 Billion KRW | 31.19% |
| 2022 Q1 | 1125.86 Billion KRW | 0.04% |
| 2022 Q2 | 1228.97 Billion KRW | 9.16% |
| 2021 Q2 | 588.72 Billion KRW | -0.22% |
| 2021 Q4 | 1125.35 Billion KRW | 6.75% |
| 2021 Q1 | 590.03 Billion KRW | 0.44% |
| 2021 FY | 1125.35 Billion KRW | 91.56% |
| 2021 Q3 | 1054.24 Billion KRW | 79.07% |
| 2020 Q1 | 238.76 Billion KRW | -4.03% |
| 2020 Q2 | 88.2 Billion KRW | -63.06% |
| 2020 Q3 | 317.62 Billion KRW | 260.08% |
| 2020 FY | 587.46 Billion KRW | 136.11% |
| 2020 Q4 | 587.46 Billion KRW | 84.96% |
| 2019 Q4 | 248.8 Billion KRW | 0.48% |
| 2019 FY | 248.8 Billion KRW | -48.82% |
| 2019 Q3 | 247.63 Billion KRW | -45.89% |
| 2019 Q2 | 457.64 Billion KRW | -3.85% |
| 2019 Q1 | 475.98 Billion KRW | -2.08% |
| 2018 FY | 486.11 Billion KRW | 19.37% |
| 2018 Q1 | 480.28 Billion KRW | 17.94% |
| 2018 Q2 | 721.41 Billion KRW | 50.21% |
| 2018 Q3 | 653.48 Billion KRW | -9.42% |
| 2018 Q4 | 486.11 Billion KRW | -25.61% |
| 2017 Q2 | 367.58 Billion KRW | 12.79% |
| 2017 Q1 | 325.9 Billion KRW | -25.82% |
| 2017 FY | 407.23 Billion KRW | -7.31% |
| 2017 Q3 | 421.5 Billion KRW | 14.67% |
| 2017 Q4 | 407.23 Billion KRW | -3.39% |
| 2016 FY | 439.36 Billion KRW | -35.56% |
| 2016 Q4 | 439.36 Billion KRW | 0.0% |
| 2015 FY | 681.79 Billion KRW | 59.6% |
| 2014 FY | 427.19 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 2.43 Billion KRW | -15388.862% |
| Green Cross Holdings Corporation | 216.35 Billion KRW | -74.436% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | -344.568% |
| Pharmicell Co., Ltd. | 390.21 Million KRW | -96613.941% |
| Green Cross Corporation | 84.89 Billion KRW | -344.568% |
| GeneOne Life Science, Inc. | 6.27 Billion KRW | -5916.401% |
| Celltrion, Inc. | 99.13 Billion KRW | -280.696% |
| SK bioscience Co.,Ltd. | 12.43 Billion KRW | -2934.681% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | -299.428% |
| Prestige BioPharma Limited | 40.87 Billion KRW | -823.375% |